NCT02171104
MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis
At risk: Primary completion moved 4 years later.
See at-risk trials from Masonic Cancer Center, University of Minnesota
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 25 versions: 16 with changes below, 9 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from Jan 5, 2026 to Jan 5, 2030
- Eligibility criteria expanded, about 35 words
- Study completion pushed from Jul 14, 2029 to Jul 14, 2031
- Secondary endpoints: details revised at 2 of 5 entries
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 100 to confirmed 149
- Primary completion date changed from estimate of Jul 14, 2026 to Jan 5, 2026
- Site details revised
- Notable Primary completion date: Jul 14, 2025 to Jul 14, 2026
- Study completion date: Jul 14, 2028 to Jul 14, 2029
- Notable Primary completion date: Sep 2022 to Jul 14, 2025
- Study completion date: Dec 2022 to Jul 14, 2028
- Notable Primary completion date: Sep 2021 to Sep 2022
- Study completion date: Dec 2021 to Dec 2022
Show 10 earlier versionsHide 10 earlier versions
- Minor Site contact updatedv18
- Notable Primary completion date: Sep 2020 to Sep 2021
- Study completion date: Sep 2020 to Dec 2021
- Notable Primary and study completion dates: Sep 2019 to Sep 2020v16
- Notable Eligibility criteria revisedv12
- Notable Primary endpoints: 1 to 2
- Eligibility criteria expanded, about 4 words
- Secondary endpoints: 4 to 5
- Minor Interventions: IMD Preparative Regimen (Drug), Osteopetrosis Haploidentical Only Preparative Regimen (Drug), Osteopetrosis Only Preparative Regimen… to IMD Preparative Regimen (Drug), Osteopetrosis Haploidentical Only Preparative Regimen (Drug), Osteopetrosis Only Preparative Regimen…
- Study site revised
- Study arms: 3 to 7
Notable Eligibility criteria expanded, about 168 wordsv8 Show 5 more changesShow less
- Start date: Jul 2014 to Jul 10, 2014
- Interventions: Alpha Lipoic Acid (Drug), Busulfan (Drug), Celecoxib (Drug), Cyclophosphamide (Drug), Cyclosporine A (CSA) (Drug), Fludarabine (Drug)… to IMD Preparative Regimen (Drug), Osteopetrosis Haploidentical Only Preparative Regimen (Drug), Osteopetrosis Only Preparative Regimen…
- Study description shortened, about 72 words
- Site contact updated
- Study arms: 1 to 3
- Minor Study arms: 0 to 1
- Study title shortened, about 2 words
- Minor Interventions: Busulfan (Drug), Cyclosporine A (Drug), Fludarabine monophosphate (Drug), Granulocyte-Colony Stimulating Factor (Drug), Methylprednisolone… to Alpha Lipoic Acid (Drug), Busulfan (Drug), Celecoxib (Drug), Cyclophosphamide (Drug), Cyclosporine A (CSA) (Drug), Fludarabine (Drug)…
- Secondary endpoints: 3 to 4
- Study description expanded, about 17 words
- Site contact updated
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Jun 2014 to Jul 2014
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (4)
Arms and interventions
Inherited Metabolic Disease (IMD) - Except Haplo-Identical See intervention descriptions.
Severe Osteoperosis (OP) - Except Haplo-Identical See intervention descriptions.
Severe Osteopetrosis (OP) and Inhterited Metabolic Disorders (IMD) -Haplo-Identical Only See intervention descriptions.
See intervention descriptions.
See intervention descriptions.
See intervention descriptions.
See intervention descriptions.
Biologicals: Stem Cell Transplantation
Drugs: IMD Preparative Regimen, Osteopetrosis Only Preparative Regimen, Osteopetrosis Haploidentical Only Preparative Regimen, cALD SR-A (Standard-Risk, Regimen A), cALD SR-B (Standard-Risk, Regimen B), cALD HR-D (High-Risk, Regimen C), cALD HR-D (High-Risk, Regimen D)
Sites
1 site in 1 country
- Masonic Cancer Center, University of MinnesotaMinneapolis, Minnesota, United States